Department of Surgery, Fukuoka City Hospital, Fukuoka, 812-0046, Japan.
Surg Today. 2011 Jun;41(6):801-5. doi: 10.1007/s00595-010-4348-3. Epub 2011 May 28.
To evaluate the trends in the treatment outcomes for patients with colorectal cancer in Japan.
We performed a retrospective analysis of patients undergoing surgery for primary colorectal cancer during a 16-year period (Group A [1992-2000, n = 258]; Group B [2001-2008, n = 258]) at Fukuoka City Hospital. Because no significant differences were found in the survival rates in stage 0, I, II, and III patients between the two groups, we concentrated on examining stage IV patients.
The 3-year survival rate for stage IV patients in Group B (n = 26) was significantly higher than that in Group A (n = 31) (34.9% vs 3.9%, P < 0.05). The rate of curative resection for advanced liver metastases in Group B patients was also significantly higher than that of Group A patients (50.0% vs 13.3%, P < 0.05). As a result, the 2-year survival rate for the disease-free patients in Group B was significantly higher than that for the non-disease-free patients in Group B (46.0% vs 21.0%, P < 0.05). Group B had a greater proportion of patients receiving l-leucovorin/5-fluorouracil than Group A (8 patients vs none, P < 0.05).
Recent advances in surgical innovations and the utilization of new chemotherapeutic agents may have led to significant improvements in the treatment outcomes for advanced colorectal cancer in Japan.
评估日本结直肠癌患者治疗结果的趋势。
我们对福冈市医院 16 年间（A 组[1992-2000 年，n=258]；B 组[2001-2008 年，n=258]）接受原发性结直肠癌手术的患者进行了回顾性分析。由于两组患者在 0 期、I 期、II 期和 III 期患者的生存率无显著差异，我们集中研究了 IV 期患者。
B 组（n=26）IV 期患者的 3 年生存率明显高于 A 组（n=31）（34.9%比 3.9%，P<0.05）。B 组患者晚期肝转移的根治性切除率也明显高于 A 组（50.0%比 13.3%，P<0.05）。因此，B 组无病患者的 2 年生存率明显高于 B 组非无病患者（46.0%比 21.0%，P<0.05）。B 组接受 l-左旋咪唑/5-氟尿嘧啶治疗的患者比例明显高于 A 组（8 例比无，P<0.05）。
外科创新和新化疗药物的应用的进步可能导致日本晚期结直肠癌治疗结果的显著改善。
